---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014547"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:49:26.064410+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M

## Summary
- Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).
- Operating expenses fell 52% to $1.5M on $3.1M in annualized cost savings from restructuring.
- Cash and cash equivalents were $4.7M as of September 30, 2024.
- Accelerated enrollment in global pilot study for TAEUS liver fat assessment; activated site at LMU Germany.
- Added AI/ML/DL features to TAEUS; IP portfolio expanded to 82 issued patents.

## SEC filing metadata
- accession: 0001654954-24-014547
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424014547/0001654954-24-014547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424014547/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014547
- JSON: https://secwatch.observer/filing/0001654954-24-014547.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.